Lifency
  • HOME
  • SERVICES
    • SALES DEVELOPMENT
    • NEW PRODUCT LAUNCH
    • NEW MARKET ENTRY
    • BRAND AWARENESS
    • FUNDING STRATEGIES
  • ABOUT US
  • CASE STUDIES
  • NEWS
Select Page
  • HOME
  • SERVICES
    • SALES DEVELOPMENT
    • NEW PRODUCT LAUNCH
    • NEW MARKET ENTRY
    • BRAND AWARENESS
    • FUNDING STRATEGIES
  • ABOUT US
  • CASE STUDIES
  • NEWS
How will mRNA – based therapeutics revolutionize the pharmaceutical industry ? 

How will mRNA – based therapeutics revolutionize the pharmaceutical industry ? 

by Jerome Puginier | Nov 22, 2022 | News

Do you have your own idea?  If you need elements of answer, we suggest reading the very exhaustive review by Musga Qureischi , Julia Mohr , Estibaliz Arellano , Sarah Elspeth Knudsen , Farrukh Vohidovn and Andoni...
Transcriptomics beyond genomics: promising clinical application

Transcriptomics beyond genomics: promising clinical application

by Jerome Puginier | Nov 18, 2022 | News

Transcriptomics, beyond genomics and beneath proteomics provide us with precious information on geneexpression and have promising clinical applications. In their recent paper Kelley Nunez et al. from Ochsner Health in New Orleans present one of them that, through a...
Is there any “magic pill“ to improve your business performance?

Is there any “magic pill“ to improve your business performance?

by Jerome Puginier | Oct 25, 2022 | News

A yes answer would not be fair… a no answer would not be true… so what? Well, think about what’s happening in your business… progress relates to the ability to diagnose and treat more and more conditions through...
The constantly changing landscape of type2 diabetes treatment

The constantly changing landscape of type2 diabetes treatment

by Jerome Puginier | Oct 20, 2022 | News

An update and indications on future directions are available in the very interesting paper* from Antea DeMarsilis just published in Metabolism  It presents each class of agents by:  ✔️mechanism of action✔️details of administration ✔️side effect profile✔️...
We support you achieving your market access objectives !

We support you achieving your market access objectives !

by Jerome Puginier | Oct 18, 2022 | News

biotech, pharma, medtech and lifescience Companies rely on us to develop their international market presence and access new b2b markets in switzerland and in the european union.  From the market access strategy to the local operations, direct or through a network of...
Proteomics allows a better understanding of the pathophysiology of Alzheimer disease

Proteomics allows a better understanding of the pathophysiology of Alzheimer disease

by Jerome Puginier | Mar 9, 2021 | News

Proteomics allows a better understanding of the physiopathology of alzheimersdisease This statement is suggested and supported by: an amazing and comprehensive paper(1) by Sruti Rayaprolu et al. from Emory University school of medicine in Atlanta explains how and why...
« Older Entries
Next Entries »

Recent Posts

  • Find the way,Walk the talk,and enlarge your World
  • Unlocking the Secrets of Cancer: SMYD2, a Promising Therapeutic Targets
  • Understanding risks of prostate cancer
  • Prostate cancer statistics and key questions
  • Advancements in Breast Cancer Care: A Decades-Long Journey Towards Improved Outcomes

LIFENCY SA

Via Fiume, 32

CH 6983 Magliaso

SWITZERLAND

CHE-381.105.035

Helpdesk

+41 76 824 20 66

info@lifency.ch

 

Follow us on

  • HOME
  • SERVICES
  • ABOUT US
  • CASE STUDIES
  • NEWS
Web Development and © by LIFENCY SA
Manage Consent
Usiamo cookie per ottimizzare il nostro sito web ed i nostri servizi.
Funzionale Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferenze
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistiche
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
Visualizza preference
{title} {title} {title}